Marco de Bruyn

List of Publications by Year
in descending order

49 papers	3,251 citations	186265 28 h-index	214800 47 g-index
51 all docs	51 docs citations	51 times ranked	4433 citing authors

#	Article	IF	Citations
1	Rapid and efficient generation of antigen‐specific isogenic T cells from cryopreserved blood samples. Immunology and Cell Biology, 2022, 100, 285-295.	2.3	0
2	Tertiary lymphoid structures critical for prognosis in endometrial cancer patients. Nature Communications, 2022, 13, 1373.	12.8	47
3	Expression of CD39 Identifies Activated Intratumoral CD8+ T Cells in Mismatch Repair Deficient Endometrial Cancer. Cancers, 2022, 14, 1924.	3.7	5
4	Automated causal inference in application to randomized controlled clinical trials. Nature Machine Intelligence, 2022, 4, 436-444.	16.0	8
5	cGAS–STING drives the IL-6-dependent survival of chromosomally instable cancers. Nature, 2022, 607, 366-373.	27.8	132
6	First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers. Molecular Therapy, 2021, 29, 611-625.	8.2	48
7	Tumor-infiltrating lymphocytes in the immunotherapy era. Cellular and Molecular Immunology, 2021, 18, 842-859.	10.5	403
8	Combined STING levels and CD103+ T cell infiltration have significant prognostic implications for patients with cervical cancer. OncoImmunology, 2021, 10, 1936391.	4.6	9
9	Design, Synthesis, and Biological Evaluation of Imidazopyridines as PD-1/PD-L1 Antagonists. ACS Medicinal Chemistry Letters, 2021, 12, 768-773.	2.8	30
10	CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration properties. Scientific Reports, 2021, 11, 20499.	3.3	11
11	Association of homozygous variants of STING1 with outcome in human cervical cancer. Cancer Science, 2021, 112, 61-71.	3.9	11
12	Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma. Clinical Cancer Research, 2020, 26, 5400-5410.	7.0	41
13	Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. Journal of Clinical Oncology, 2020, 38, 3388-3397.	1.6	398
14	Transcriptional Activity and Stability of CD39+CD103+CD8+ T Cells in Human High-Grade Endometrial Cancer. International Journal of Molecular Sciences, 2020, 21, 3770.	4.1	13
15	Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcome. OncoImmunology, 2020, 9, 1760705.	4.6	11
16	Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer. Cancer Immunology Research, 2020, 8, 1508-1519.	3.4	45
17	171…Preclinical studies support therapeutic application of the leukemic cell-based cancer relapse vaccine DCP-001 in ovarian cancer. , 2020, , .		0
18	Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis. Nature Communications, 2019, 10, 533.	12.8	26

#	Article	IF	Citations
19	A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer. Cancer Immunology Research, 2019, 7, 784-796.	3.4	141
20	MAPK pathway activity plays a key role in PDâ€L1 expression of lung adenocarcinoma cells. Journal of Pathology, 2019, 249, 52-64.	4.5	117
21	Antigen-specific active immunotherapy for ovarian cancer. The Cochrane Library, 2018, 9, CD007287.	2.8	11
22	Lymphadenectomy and Adjuvant Therapy Improve Survival with Uterine Carcinosarcoma: A Large Retrospective Cohort Study. Oncology, 2018, 95, 100-108.	1.9	15
23	Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative. Modern Pathology, 2018, 31, 1851-1861.	5.5	35
24	Immunological profiling of molecularly classified high-risk endometrial cancers identifies *POLE*-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. OncoImmunology, 2017, 6, e1264565.	4.6	102
25	CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer. OncoImmunology, 2017, 6, e1338230.	4.6	116
26	Microsatellite instability derived *JAK1* frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer. Oncotarget, 2016, 7, 39885-39893.	1.8	29
27	CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma. European Journal of Cancer, 2016, 60, 1-11.	2.8	125
28	Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. The Lancet Gastroenterology and Hepatology, 2016, 1, 207-216.	8.1	227
29	Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2016, 22, 714-724.	7.0	51
30	CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy. Oncotarget, 2016, 7, 75130-75144.	1.8	64
31	*POLE* Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. Clinical Cancer Research, 2015, 21, 3347-3355.	7.0	249
32	The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux. Autophagy, 2015, 11, 1373-1388.	9.1	49
33	The Ever-Expanding Immunomodulatory Role of Calreticulin in Cancer Immunity. Frontiers in Oncology, 2015, 5, 35.	2.8	36
34	CD20+T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancer. OncoImmunology, 2015, 4, e999536.	4.6	17
35	C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity. MAbs, 2015, 7, 321-330.	5.2	22
36	CD20+inflammatory T-cells are present in blood and brain of multiple sclerosis patients and can be selectively targeted for apoptotic elimination. Multiple Sclerosis and Related Disorders, 2014, 3, 650-658.	2.0	49

#	Article	IF	Citations
37	Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death. Molecular Cancer, 2014, 13, 85.	19.2	21
38	Therapeutic potential of Galectin‑9 in human disease. Medicinal Research Reviews, 2013, 33, E102-26.	10.5	120
39	Antibody-based fusion proteins to target death receptors in cancer. Cancer Letters, 2013, 332, 175-183.	7.2	46
40	In Vivo Responses of Human A375M Melanoma to a Ïƒ Ligand: 18F-FDG PET Imaging. Journal of Nuclear Medicine, 2013, 54, 1613-1620.	5.0	7
41	The Glycan-Binding Protein Galectin-9 Has Direct Apoptotic Activity toward Melanoma Cells. Journal of Investigative Dermatology, 2012, 132, 2302-2305.	0.7	35
42	Frequency of Th17 CD20+ cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjects. Arthritis Research and Therapy, 2011, 13, R208.	3.5	56
43	Selective elimination of pathogenic synovial fluid T-cells from Rheumatoid Arthritis and Juvenile Idiopathic Arthritis by targeted activation of Fas-apoptotic signaling. Immunology Letters, 2011, 138, 161-168.	2.5	15
44	Cell Surface Delivery of TRAIL Strongly Augments the Tumoricidal Activity of T Cells. Clinical Cancer Research, 2011, 17, 5626-5637.	7.0	32
45	Carbon monoxide-Releasing Molecule-2 (CORM-2) attenuates acute hepatic ischemia reperfusion injury in rats. BMC Gastroenterology, 2010, 10, 42.	2.0	80
46	Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo. Molecular Cancer, 2010, 9, 301.	19.2	58
47	Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells. Journal of Molecular Medicine, 2008, 86, 909-924.	3.9	37
48	Potent Systemic Anticancer Activity of Adenovirally Expressed EGFR-Selective TRAIL Fusion Protein. Molecular Therapy, 2008, 16, 1919-1926.	8.2	29
49	Both exposure to a novel context and associative learning induce an upregulation of AKAP150 protein in mouse hippocampus. Neurobiology of Learning and Memory, 2007, 87, 693-696.	1.9	17